|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's range||26.800 - 31.000|
|52-week range||14.600 - 37.050|
|PE ratio (TTM)||22.31|
|Earnings date||6 Feb 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||34.40|
Primecap Management is known for its stock-picking prowess, particularly in this age of passivity. The fund shop is also known for its penchant for privacy.We profiled the company in 2016 by speaking with people familiar with the company, but none of the listed managers would speak to us on the record. In its first regulatory filings this year, however, Primecap has tipped its hand to the public by disclosing the acquisition of more shares of Alkermes (ALKS) and Flex Pharma (FLKS) while trimming back on Axcelis Technologies (ACLS).
Axcelis Technologies (ACLS) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Axcelis Technologies was already up 70% this year when Aalok Devkota added it to his portfolio in September at $24. A lot of people would have waited for a pullback before buying. It's a good thing Aalok didn't. The stock has run up another 42%, and now Aalok is selling.
Infosys (INFY) partners with Udacity to train employees in Self-Driving Car Engineer Nanodegree program, which will offer the company's employees a combined in-person and online training.
On a per-share basis, the Beverly, Massachusetts-based company said it had profit of 35 cents. Earnings, adjusted for non-recurring costs, were 38 cents per share. The results exceeded Wall Street expectations. ...
Axcelis Technologies (ACLS) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.